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Resumo
Introdução: A pancreatite aguda (PA) por hipertrigliceridemia 
(HTG) pode ser tratada com troca plasmática terapêutica (TPT), 
com redução rápida dos valores de triglicerídeos. Contudo, não 
existem	 estudos	 comparativos	 definitivos	 que	 comprovem	 o	
real benefício desta terapêutica. 
Objetivo: Comparação dos métodos de tratamento (troca plas-
mática terapêutica versus convencional) em doentes com PA 
HTG, durante um período de 12 anos (2000-2012). 
Métodos: Estudo	 retrospetivo	 descritivo	 e	 inferencial	 de	 37	
doentes, avaliando: sexo, idade, antecedentes pessoais, gravi-
dade, valores de TG e evolução consoante o tratamento (“TPT” 
ou terapêutica convencional “C”). 
Resultados: Os dois grupos TPT e C mostraram-se homogéneos 
quanto ao sexo (p	=	0,647),	idade	(43,5	±	9,74	anos	TPT	versus 
45,30 ± 9,90 anos C; p	=	0.320),	pancreatite	prévia	(40%	TPT	vs 
40,7%	C;	p	=	1,0)	alcoolismo	crónico	(50%	TPT	vs	70,4%	C;	p	=	
0,275)	e	gravidade	pelo	score de APACHE II (p	=	0,054)	e	Ran-
son às 48 horas (p	=	0,258).	Dos	doentes	45,95%	apresentava	
mais de um fator de risco secundário para HTG. O grupo TPT 
apresentou maiores valores de TG à admissão: 4850 ± 2802 
mg/dL	vs 1845	±	1858	mg/dL	(p	=	0,001).	Não	se	verificaram	di-




(p	=	0,002).	De	referir	seis	intercorrências	minor durante a troca 
plasmática terapêutica. 
Discussão/Conclusões: Apesar do viés de seleção (estudo re-
trospetivo), foi constatada uma maior redução dos TG por esta 
técnica. As intercorrências inerentes à técnica de troca plasmá-
tica terapêutica foram de simples resolução.
Palavras-chave:	 Doença	 Aguda;	 Hipertrigliceridémia/trata-
mento;	Pancreatite/tratamento;	Troca	Plasmática.
Abstract
Introduction: Acute pancreatitis (AP) induced by hypertriglyc-
eridemia (HTG) can be treated with therapeutic plasma ex-
change (TPE), resulting in rapid reduction of triglyceride lev-
el. However, there are no definitive comparative studies that 
prove the real benefits of this therapy. 
Objectives: Comparison of treatment methods (TPE versus 
conventional) in patients with HTG AP during a period of 12 
years (2000-2012). 
Methods: Retrospective, descriptive and inferential analysis of 
37 patients, evaluating: gender, age, personal pathologic his-
tory, severity of disease, HTG values and evolution depend-
ing on treatment with therapeutic plasma exchange (“TPE”) or 
with conventional therapy (“C”). 
Results: Both groups TPE and C demonstrated homogeneity 
considering gender (p = 0.647), age (43.5 ± 9.74 years TPE vs 
45.30 ± 9.90 years C; p = 0.320), prior AP episode (40% TPE 
vs 40.7% C; p = 1.0), chronic alcohol consumption (50% TPE 
vs 70.4% C; p = 0.275) and severity disease scores: APACHE 
II (p = 0.054) and Ranson (p = 0.258). More than one sec-
ondary HTG risk factor was presented in 45.95% of patients 
. TPE group presented higher TG levels at admission: 4850 
± 2802 mg/dL vs 1845 ± 1858 mg/dL (p = 0.001). No signifi-
cant statistical differences were observed considering length 
of hospital stay [14.2 ± 6.8 days vs 13.5 ± 9.0 days (p = 0.56)] 
or mortality rate (p = 0.47). At discharge, TG reduction was 
greater in TPE group: 4433.70 ± 2896.08 mg/dL – 91.41% vs 
1582.95 ± 2051.06 mg/dL – 83,92% (p = 0.002). Six minor 
complications associated to TPE occurred. 
Discussion/Conclusion: Despite the selection bias (retrospec-
tive study), a greater TG reduction was observed with TPE 
technique. Complications associated with the technique were 
simple to resolve.
Keywords: Acute Disease; Hypertriglyceridemia/therapy; Pan-
creatitis/therapy; Plasma Exchange.
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Introduction
Acute pancreatitis (AP) is a potentially life-threatening con-
dition,	 with	 a	 worldwide	 rising	 incidence.	 It	 is	 defined	 as	
an	acute	 inflammatory	process	 involving	 the	pancreas,	pe-
ripancreatic tissue and remote organ systems.1–4 The most 
prevalent causes are gallstone disease, alcohol abuse and 
hypertriglyceridemia	(HTG),	with	HTG	accounting	for	1-7%	of	
cases, depending on the series.3,5,6
It is commonly accepted that a triglyceride (TG) level > 
1000	mg/dL	(>	11.3	mmol/L)	 is	necessary	 to	 trigger	an	AP.	
However, there is no clear threshold for TG level. TG levels 
between	500	and	1000	mg/dL	should	raise	a	high	degree	of	
suspicion, particularly if accompanied by lactescent serum, if 
the evaluation of TG level has been delayed or if there is no 
other obvious etiology.3,5–9
HTG can be either primary (rare cases of genetic determi-
ned	dyslipidemias	–	Frederickson	Classification	I,	IV	and	V)	or	
secondary, usually multifactorial, consequent to an associa-
tion of a large number of genetic polymorphisms, and lifestyle 
or acquired conditions (autoimmune disease, chronic kidney 
disease, diabetes mellitus, drugs, hypothyroidism, metabolic 
syndrome, obesity and pregnancy).1,3,8,10,11 The classic por-
trait of an AP induced by HTG is a patient with a preexisting 
lipid abnormality, along with the presence of a secondary 
factor (such as being a poorly controlled diabetic, the use of 
retinoids or other associated medications, alcohol abuse or 
pregnancy).4,5,8,12
The pathophysiologic mechanism by which HTG causes 
AP is still unclear. Several theories have been proposed, most 
of them describing free fatty acids as the cornerstone toxic 
molecule. Despite TG not being toxic themselves, they serve 
as a source of unsaturated fatty acids.3,5,7,8,13,14 Hence there 
was a need for development of treatment forms that promote 
rapid removal of excessive TG, contrasting with conventio-
nal treatment (pancreas rest, analgesia, supportive care for 
organ failure, and complications management). Even though 
the	 first	 case	 report	 of	 therapeutic	plasma	exchange	 (TPE)	
use	in	AP	secondary	to	HTG	dates	of	1978,	and	most	studies	
describe	a	rapid	TG	reduction	(up	to	60-80%	after	one	or	two	
sessions), it remains a poorly studied treatment.12,14–16 This 
is owing to its costs, poor accessibility and fear of potential 
complications, which limited the studies mostly to small case 
series and case reports, resulting in a weak recommendation 
in guidelines.1,7,10,12–14,16,17
Considering what was described, the authors developed 
the present study to characterize and compare treatment 
methods (TPE versus conventional) in patients with HTG AP, 
during a period of 12 years (2000-2012).
Material and Methods
A retrospective, descriptive and inferential analysis was con-
ducted, involving patients admitted to our Hospital (Hospitais 
da Universidade de Coimbra) from January 2000 to Decem-
ber 2012 (13-year period).
A	control	group	(conservative	treatment	–	“C”)	was	obtained	
through the analysis of the Hospital discharge documents da-
tabase, selecting patients admitted to the Internal Medicine 
ward with the clinical diagnosis of AP, which corresponded 
to	347	patients.	Exclusion	criteria	for	the	control	group	were:	
gallstone	disease	 (identified	 in	 ultrasound	 imaging	or	 other	
imaging exam), isolated alcohol abuse, potentially iatrogenic 




The TPE group (TPE treatment - “TPE”), was obtained 
through the analysis of the Blood Bank and Transfusion Me-
dicine	 Department	 TPE	 database,	 with	 identification	 of	 11	
patients. Exclusion criteria were the same as for the control 
group, except these patients had to have been treated with 
TPE. Patients submitted to TPE for any other condition were 
also excluded. A total of 10 patients were selected, submitted 
to a total of 23 sessions. In all TPE sessions albumin was used 
as	fluid	replacement	and	anticoagulation	was	obtained	with	
citrate.
Both groups were included in the analysis, preserving the 
anonymity of the patients and considering: age, sex, previous 
pathologic conditions, medications, clinical presentation, se-
verity score index of AP (Ranson’s criteria and APACHE II 
score - Acute Physiology and Chronic Health Disease Clas-
sification	System	II),	blood	analyses,	 including	TG	and	total	
cholesterol levels, complications (associated or not to AP or 
its treatment), evolution and mortality.
Statistical analysis was performed using IBM SPSS Statis-
tics 20.0®. Inferential analysis of nominal variables was per-
formed according to Cochran rules, using Fisher’s exact test 
or	chi-square	test	(χ2). Continuous variables were tested for 
normality distribution with Shapiro-Wilk’s test. Analysis of con-
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tinuous variables was performed with Mann-Whitney’s test (U 
–	nonparametric	 test	 for	 non-normally	distributed	variables)	
or	Student’s	t	test	(t	–	parametric	test	for	normally	distributed	
variables, after assessment of equality of variances using Le-
vene’s test). A p-value of less than 0.05 was considered to 
indicate	statistical	significance	(type	I	error).
Results
As presented in Table 1 most of the patients were young 
(mean	age	of	44.81	±	9.75	years),	males	(81.08%),	frequently	
with prior diagnosis of lipid disorder (3 patients with known 
HTG	 hereditary	 syndromes,	 without	 specific	 Fredrickson	
classification	–	two	in	the	TPE	group	and	one	in	the	C	group).	
The most common secondary factors were alcohol consump-
tion	(64.86%),	metabolic	syndrome	(45.95%)	and	type	2	dia-
betes	 mellitus	 (27.03%).	 Considering	 drugs	 as	 secondary	
factors for HTG, two patients where on beta-blockers (one 
in each group) and the remaining patients where on thiazide 
diuretics. One patient was diagnosed with HIV (human im-
munodeficiency	virus)	infection	but	only	started	antiretroviral	
treatment after the AP episode. Apart from body mass index 
(p	=	0.041),	the	characteristics	observed	in	Table	1	show	ho-
mogeneity in both groups.
Table 2 shows the clinical presentation of the patients at 
admission (in all cases, the presentation in the emergency de-
partment).	There	were	statistically	significant	differences	in	the	
evaluation of heart and respiratory rates (p	=	0.017	and	p	=	
0.004 respectively). Although both parameters are important 
for the calculation of APACHE II Score, there is no statistically 
significant	difference	between	the	groups	as	seen	 in	Table	3	
(representing also other parameters related to the initial labo-
ratory and clinical evaluation). Eight patients (all from the TPE 
group) were admitted to the Gastroenterology Intensive Care 
Unit	(UCIGE),	with	a	mean	length	of	stay	of	6.63	±	3.78	days.







Test Test value P df








χ2 (F) - 0.647 1
BMI	(kg/m2) 26.30 ± 4.85 29.73	±	3.00 U 67.000 0.041 N	-	1
Prior pancreatites 40.74%	(11) 40.00%	(4) χ2 (F) - 1.000 1




















































































Drugs: 2 patients with beta-blockers and 3 patients with thiazide diuretics; 3 patients with knowledge of prior lipid disorder - familiar hypercholesterolemia (2P, 
1C);
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A total of 23 TPE sessions were performed (minimum of one 
session and maximum of four sessions), with the decrease in TG 
level being represented in Fig. 1 (as well as TG variation of the C 
group and total cholesterol variation in both groups). Complica-
tions	were	identified	in	26.09%	(six	patients)	of	all	TPE	sessions	
(Table 4). All were quickly and effectively solved: an anxiety atta-
ck solved by stopping the session, paresthesia treated with cal-
cium gluconate, urticaria treated with clemastine and treatment 
induced	pain	worsening	 treated	with	 different	 analgesics.	No	
other complications related to TPE were documented. TG levels 
after	the	first	TPE	cycle	were	only	available	for	eight	patients.	For	




four from TPE group and seven from the C group. Fibrates were 
early introduced during treatment in six cases (two patients from 
TPE group and four from the C group).
One patient from the TPE group was discharged against me-
dical advice, prior to optimal lipid care, and one patient (also 
from the TPE group) was transferred to another hospital (closer 
to the area of residence of the patient) to continue treatment.
Discussion
This	study	included	37	patients	(Table	1)	most	of	them	were	
young males, with prior diagnosis of lipid disorder. Seventeen 
patients	had	more	than	one	secondary	risk	factor	(45.95%),	
which demonstrates higher risk compared to other popula-
tions (data from a systematic study demonstrates accumula-
tion	of	risk	factors	in	9.4%	of	the	patients).7  All our other de-
mographic data is coincident with previous studies (including 
a recent systematic review of 301 patients)7,16 and there are 
no	statistically	significant	differences	between	the	two	groups	
(apart from body mass index, p	=	0.041,	but	with	both	groups	
presenting	overweight/obesity),	demonstrating	homogeneity	
between groups TPE and C.
At clinical presentation (Table 2), some differences be-
tween groups C and TPE are apparent, but merely conside-
ring heart rate and respiratory rate (p	=	0.017	and	p	=	0.004).	
As AP usually presents as an acute onset of abdominal pain, 
homogeneity between groups was expected. Clinical signs 
and symptoms associated with initial laboratory evaluation 
(Table 3) allow calculation of scores like APACHE II and Ran-
son, that accurately predict outcome of patients with acute 
pancreatitis.18	Although	 there	was	no	statistically	 significant	
























































































Xanthomas	/	Xanthelasma 0 10.00%	(1) χ2 (F) - 0.278 1
Nominal	variables	are	presented	by	relative	frequency.	Continuous	variables	are	presented	by	mean	±	standard	deviation.	χ2	chi-squared	test;	df	–	degrees	
of	freedom;	F	-	Fisher´s	exact	test;	U	-	Mann-Whitney	test;	t	-	student-t	test;	°C	-	degrees	Celsius;	bpm	(heart	rate)	-	beats	per	minute;	bpm	(respiratory	rate)	-	
breaths per minute; mm Hg - millimeter of mercury.
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differences between the scores of groups C and TPE (p	=	
0.054 for APACHE II and p	=	0.258	 for	Ranson)	calculated	
scores should be analyzed in more detail. The group sub-
mitted to TPE presented APACHE II scores of 9.56 ± 4.82, 
much	higher	than	the	same	value	for	C	group	–	6.55	±	2.86,	
associated to a potentially higher hospital mortality. As the 
present study is retrospective, this type of bias was expected, 
as patients in worst clinical state are treated more aggressi-
vely and, therefore, most promptly selected for TPE (this kind 
of bias was present also in a systematic review of cases7). In 
this case, the low number of patients included in the study is 
probably the reason why there are no statistical differences.
Another expected bias is TG total level at admission. As pre-
viously stated, standard treatment of AP includes pancreas rest, 
analgesia, supportive care for organ failure, and management 
of complications. However, a rapid decrease in TG levels is 
essential to the successful management of HTG induced pan-
creatitis.10 Several studies report decreases in TG levels after 
only	one	session	of	TPE	in	up	to	60%	of	patients,	and	up	to	60-
80%	in	one	or	two	sessions.3,7,10,12,16	Considering these results, 
a bias of selection of patients with high TG levels at admission 
to TPE is logical (as well as a selection bias for the patients 
admitted in the UCIGE). Similar reduction results were obtained 
in	 our	 study	 (Table	4),	with	decrease	 in	TG	up	 to	80.97%	 in	
one session (results considering data from eight patients) and 
up	to	91.41%	at	the	end	of	all	sessions	for	patients	submitted	
to more than one treatment (six patients). Similar results were 
obtained for total cholesterol level decrease. Regardless of 
selection bias and premature discharge of two patients in the 
TPE group (one patient against medical advice and one patient 
transferred to another hospital), the relative reduction achieved 
in the TPE treatment group was greater than in the conventio-
nal treatment group (p	=	0.002	both	in	TG	and	total	choleste-
rol levels reduction), demonstrating that TPE is a useful tool for 
achieving	an	early	decrease	of	TG	to	safer	levels.	The	benefits	
of this treatment acquire a greater importance given that some 
studies	demonstrate	 that	TG	 levels	<	500	mg/dL	represent	a	
safe therapeutic target, not only to prevent AP recurrences, but 
also to prevent other clinical events (cardiovascular, diabetes 
and renal) and to reduce overall costs.12







Test Test value P df
Complete blood count 
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Although	TPE	has	proven	effective	in	achieving	significant	
reductions in TG levels, most studies are case reports and 
small case series. Randomized controlled trials are lacking 









Test Test value P df
Length of stay (days) 13.48 ± 9.03 14.20	±	6.76 U 118.000 0.560 N	-	1



































































































































Lipid evolution: Triglycerides 
Triglycerides	at	admition	(mg/dL)
Triglycerides after one session of 
plasmapheresis	(mg/dL)*


































Lipid evolution: Total cholesterol
Total	cholesterol	at	admition	(mg/dL)
Total cholesterol  after one session 
of	plasmapheresis	(mg/dL)*
Total cholesterol  after one session 
of plasmapheresis reduction
Total	cholesterol	at	discharge	(mg/dL)






































and, consequently, guidelines such as the latest from the 
American	Society	for	Apheresis	classifies	TPE	as	a	category	
III indication in HTG induced AP.19 These studies are lacking 
REVISTA DA SOCIEDADE PORTUGUESA DE MEDICINA INTERNA
Medicina Interna 104
PANCREATITE HIPERTRIGLICERIDÉMICA
not only because of the limited availability of this kind of treat-
ment and low prevalence of the disease, but also because 
of the fear of potential complications. Some complications of 
TPE	 are	 bleeding/hematoma,	 catheter	 site	 infection,	 hemo-
thorax,	hypofibrinogenemia,	hypotension,	nausea,	paresthe-
sia (associated to the use of citrate as anticoagulation thera-
py and consequent hypocalcemia), pneumothorax, urticaria, 
vasovagal reactions and vomiting.17 However, studies have 
demonstrated that the occurrence of truly important compli-
cations is rare, and that most complications, like clinical mani-
festation of hypocalcemia by paresthesia is easily treated.6,10 
This data is concurrent with that of our study, with only minor 
complications associated to TPE being documented.
It is also important to consider the length of the study (13 
years), as it entails technological and practical changes that 
may represent a bias, not only in the rate of complications but 
also on the clinical evolution.
Considering the length of hospital stay and mortality, no 
statistically	 significant	 differences	 were	 achieved	 between	
both groups [p	 =	 0.560	and	p	 =	 0.473	 respectively	 (Table	
4)].	These	data	are	similar	 to	a	previous	study,	by	Chen et 
al,20 that	showed	no	clear	benefit	of	apheresis	in	reducing	se-
verity and improving outcomes in AP.12,15,16	 Nevertheless,	 it	
is important to emphasize that study presented similar bias 
and limitations as our present study: it is also a retrospecti-
ve study, with small groups (60 patients treated with TPE; 34 
patients treated otherwise) and single center experience (as 
it was designed for the evaluation of the clinical outcomes in 
HTG induced AP before and after the availability of apheresis 
at their institution). On the other hand, major AP complica-
tions (pancreatic pseudocyst and pancreatic abscess) were 
more commonly seen in the group treated with conventional 
therapy. Although the number of cases is too small in order to 
properly	achieve	definitive	considerations,	 rapid	 removal	of	
TG may reduce damage to the pancreas. Still, further studies 
are needed.
Many questions remain unanswered, not only considering 
the	 real	benefit	of	 the	use	of	TPE,	but	also	considering	va-
riations	on	the	technique	(a	recent	study	found	a	significant	
reduced mortality using citrate anticoagulation as compared 
to heparin anticoagulation).3
Conclusions
Apart from the greater burden of secondary factors, our study 
reported a population that has general demographic data si-
milar to what has been previously published in studies about 
AP induced by HTG. This can potentially illustrate greater in-
cidence	and/or	more	severe	cases,	conclusions	that	require	
further studies.
We also reported how therapeutic plasma exchange can 
effectively and quickly reduce TG levels, to a safe thera-
peutic target without major complications associated to the 
treatment.	 There	 was	 no	 statistically	 significant	 differences	
between patients treated with or without TPE, regarding len-
gth of hospital stay and mortality, but the small sample in this 
study may contribute to this result. Well design randomized 
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